BioAge Labs Announces First Participant Dosed In Quell-Dme, A Phase 2 Trial Of Bge-102, A Novel Oral Nlrp3 Inhibitor, In Diabetic Macular Edema
BIOA•First participant dosed in Phase 2 trial
Sept. 8 (Reuters) - BioAge Labs, Inc. BIOA.O:
- BioAge Labs announces first participant dosed in Quell-DME, a Phase 2 trial of BGE-102, a novel oral NLRP3 inhibitor, in diabetic macular edema.
- BioAge Labs said topline results from the Quell-DME trial are expected in the second half of 2027.
